If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Researchers have identified new lung function and blood test cutoffs to improve timely chronic hypercapnia management in ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Your COPD is considered to be moderate ... s stage allows your doctor to recommend and prescribe the best possible treatment. While staging helps create standard treatments, your doctor will ...

It's the first ever biologic medicine for COPD in either country. Specifically, the drug is indicated in both countries as an add-on treatment for patients with inadequately controlled COPD and an ...

You will likely need to make lifestyle changes, in addition to taking prescribed medications, to prevent the condition from worsening. It’s best to talk with your doctor if you suspect COPD or ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Personalized Medicine. 2014;11(7):669-679. In this article, we will describe the current status of personalized medicine for chronic, complex diseases using chronic obstructive pulmonary disease ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...